Canada finally opens up data on new drugs and devices: Other regulators should take note of Health Canada’s substantive reforms

dc.contributor.author	Doshi, Peter
dc.date.accessioned	2019-04-19T14:31:17Z
dc.date.available	2019-04-19T14:31:17Z
dc.date.issued	2019-04-17
dc.identifier.uri	http://hdl.handle.net/10713/8860
dc.description	Authors discuss Health Canada’s revised regulations regarding releasing detailed clinical information about new drugs, biological treatments, and medical devices. They contrast the policies of the Canadian regulator and its European counterpart, the European Medicines Agency (EMA), with that of the US Food and Drug Administration (FDA) which has yet to demonstrate a similar commitment to transparency.	en_US
dc.description.uri	https://doi.org/10.1136/bmj.l1825	en_US
dc.language.iso	en_US	en_US
dc.publisher	BMJ Publishing Group	en_US
dc.subject	clinical study reports	en_US
dc.subject	data access policies	en_US
dc.subject	research transparency	en_US
dc.subject.lcsh	Canada. Health Canada	en_US
dc.subject.lcsh	European Medicines Agency	en_US
dc.subject.lcsh	United States. Food and Drug Administration	en_US
dc.subject.mesh	Information Dissemination--legislation & jurisprudence	en_US
dc.title	Canada finally opens up data on new drugs and devices: Other regulators should take note of Health Canada’s substantive reforms	en_US
dc.type	Article	en_US
dc.identifier.doi	10.1136/bmj.l1825
dc.identifier.ispublished	Yes	en_US